MARKET

ZGNX

ZGNX

Zogenix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.56
-0.55
-3.01%
Opening 11:01 06/22 EDT
OPEN
18.02
PREV CLOSE
18.10
HIGH
18.07
LOW
17.52
VOLUME
55.77K
TURNOVER
--
52 WEEK HIGH
32.42
52 WEEK LOW
16.73
MARKET CAP
979.79M
P/E (TTM)
-4.0802
1D
5D
1M
3M
1Y
5Y
Zogenix to Participate in Two Upcoming Investor Conferences
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that members of its management team will participate in two upcoming investor conferences: the Raymond James Human Health Inno...
GlobeNewswire · 1d ago
Zogenix gains after speculation on potential activist investor
Maksim Labkouski/iStock via Getty Images Zogenix (ZGNX) rose 3.6% after speculation that the company could potentially attract an activist. Zogenix could be an activist target as it shares have underperformed peers,
Seekingalpha · 6d ago
Zogenix, Inc. (NASDAQ:ZGNX) Insiders Increased Their Holdings
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Simply Wall St. · 05/25 12:46
Novo A Buys Spruce Biosciences Inc, Alibaba Group Holding, Kinnate Biopharma Inc, Sells ...
GuruFocus News · 05/21 21:38
Prosight Management, LP Buys Galapagos NV, Kezar Life Sciences Inc, Oscar Health Inc, Sells ...
GuruFocus News · 05/14 20:38
Bridger Management, Llc Buys Sotera Health Co, Microsoft Corp, Insulet Corp, Sells American ...
GuruFocus News · 05/14 19:38
Insider Trends: Zogenix Insider 90-Day Buying Trend Prolonged with Purchase
MT Newswires · 05/12 20:03
Zogenix to Participate in the BofA Securities 2021 Healthcare Conference
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financi...
GlobeNewswire · 05/11 20:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZGNX. Analyze the recent business situations of Zogenix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZGNX stock price target is 48.70 with a high estimate of 65.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 255
Institutional Holdings: 71.58M
% Owned: 128.24%
Shares Outstanding: 55.81M
TypeInstitutionsShares
Increased
40
4.32M
New
20
2.90M
Decreased
58
4.05M
Sold Out
21
1.07M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.62%
Pharmaceuticals & Medical Research
-0.47%
Key Executives
Non-Executive Chairman/Independent Director
Cam Garner
President/Chief Executive Officer/Director
Stephen Farr
Chief Financial Officer/Executive Vice President/Treasurer/Secretary
Michael Smith
Executive Vice President/General Counsel/Secretary
Shawnte Mitchell
Executive Vice President
Gail Farfel
Executive Vice President
Bradley Galer
Executive Vice President
Ashish Sagrolikar
Independent Director
Louis Bock
Independent Director
James Breitmeyer
Independent Director
Caroline Loewy
Independent Director
Erle Mast
Independent Director
Mary Stutts
Independent Director
Renee Tannenbaum
Independent Director
Denelle Waynick
Independent Director
Mark Wiggins
No Data
About ZGNX
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Webull offers kinds of Zogenix, Inc. stock information, including NASDAQ:ZGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZGNX stock methods without spending real money on the virtual paper trading platform.